| Patient | Evel Knievel |
|---|---|
| Date of birth | 1968-10-17 |
| Identifiers | MRN HR-RB001-SYN; SSN (made up) 000-01-4927 |
| Document date | 2026-08-17 |
| Author | Dale Rasmussen, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Test of cure for hepatitis C and six-month liver cancer surveillance. [S]
Mr. Knievel returns 13 weeks after his last dose of sofosbuvir-velpatasvir. The surveillance ultrasound a week ago showed no liver lesion. He had the zoledronic acid infusion eleven weeks ago, with a day of aches afterwards. His eye examination in June showed no diabetic retinopathy. He has had no alcohol since February. He takes carvedilol 12.5 mg daily. Pain is about 4 of 10 and he walks 30 minutes most days. He has had no falls, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Cure | HCV RNA not detected 13 weeks after treatment |
| Surveillance | Ultrasound a week ago: no lesion; alpha-fetoprotein 3.4 ng/mL |
| Liver function | Child-Pugh A5; MELD-Na 6 |
| Bone | Zoledronic acid given eleven weeks ago |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight steady |
| Gastrointestinal | Negative | No abdominal swelling, black stools or vomiting of blood |
| Musculoskeletal | Positive | Hip and knee pain, 4 of 10 |
| Neurological | Negative | No confusion or tremor |
| Endocrine | Negative | No low glucose readings |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet twice daily with breakfast and supper | Oral route | 2021-03-01 | active | S |
| Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back pain | One tablet three times a day | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofen | One capsule daily before breakfast | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day | Two tablets up to twice a day as needed; no more than 2 g a day | Oral route | 2026-01-12 | active | S |
| Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day | 4 g to each knee up to four times a day | Topical route | 2026-01-12 | active | S |
| Carvedilol 6.25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 to 2026-02-23 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 | active | S |
| Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeks | One tablet daily for 12 weeks | Oral route | 2026-02-23 to 2026-05-17 | completed | S |
| Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-02-23 | active | S |
| Zoledronic acid 5 mg in 100 mL, intravenous infusion over at least 15 minutes, once a year | Once a year | Intravenous route | 2026-06-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-17 | Body height | 178 | cm | S |
| 2026-08-17 | Body weight | 82.6 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 26.1 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 60 | /min | S |
| 2026-08-17 | Respiratory rate | 14 | /min | S |
| 2026-08-17 | Body temperature | 36.6 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-17 | Hemoglobin [Mass/volume] in Blood | 14.4 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-08-17 | Leukocytes [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-08-17 | Platelets [#/volume] in Blood by Automated count | 134 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-08-17 | Creatinine [Mass/volume] in Serum or Plasma | 0.88 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 100 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-17 | Glucose [Mass/volume] in Serum or Plasma | 112 | mg/dL | 70-99 mg/dL | High | S |
| 2026-08-17 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 2026-08-17 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 8-48 U/L | Normal | S |
| 2026-08-17 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 92 | U/L | 40-129 U/L | Normal | S |
| 2026-08-17 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-08-17 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-08-17 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.9-1.1 | Normal | S |
| 2026-08-17 | Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | [IU]/mL | Not detected is reported as 0; lower limit of quantification 15 IU/mL | Normal | S |
| 2026-08-17 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 3.4 | ng/mL | <=8.3 ng/mL | Normal | S |
| 2026-08-17 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.3 | % | Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosis | High | S |
| 2026-08-17 | Glucose management indicator | 6.8 | % | Individual goal below 7% | Normal | S |
| 2026-08-17 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-08-17 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | {score} | S |
Vital signs recorded on 2026-08-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 82.6 kg; blood pressure 120/74, pulse 60 |
| Skin | A few spider angiomas; no jaundice |
| Abdomen | Spleen tip palpable; no ascites |
| Neurological | No asterixis; gait steady |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered | resolved | confirmed | R74.01 | S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation. |
| Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis C | resolved | confirmed | B18.2 | S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D). |
| Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleeding | active | confirmed | K74.69 | S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant. |
| Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII) | active | confirmed | K76.6 | S — Synthetic finding at the hepatology consultation. |
| Type 2 diabetes on metformin, A1c 7.4% | active | confirmed | E11.65 | S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice. |
| Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids | active | confirmed | G89.29 | S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years. |
| Osteoporosis in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: femoral neck T-score -2.6, lumbar spine -1.9 | active | confirmed | M81.8 | S — Synthetic bone density result. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding before the bone density scan. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HCV RNA 12 or more weeks after treatment (SVR12) | Once, 12 or more weeks after the last dose | Completed today | Not detected: cured |
| Laboratory | Hepatic function panel after treatment | With the test of cure | Completed today | ALT 22, AST 26, alkaline phosphatase 92 U/L, bilirubin 0.8 mg/dL, albumin 4.0 g/dL |
| Laboratory | Blood count, INR and kidney function in cirrhosis | Every six months | Completed today | Platelets 134, hemoglobin 14.4 g/dL, white cells 5.2; INR 1.0; creatinine 0.88 mg/dL, eGFR 100 |
| Examination | Child-Pugh class and MELD-Na | Every six months in cirrhosis | Completed today | Child-Pugh A5; MELD-Na 6 |
| Imaging | Liver ultrasound for cancer surveillance at six months | Every six months in cirrhosis | Deferred | A deviation: due six months after the baseline scan, in July, but done a week ago, about three weeks late, because the recall was set from the hepatology visit and then held until after the test of cure. No harm resulted: no lesion (LI-RADS US-1). Corrective action: the recall is now set from the date of each scan, every six months |
| Laboratory | Alpha-fetoprotein with surveillance ultrasound | Every six months with ultrasound | Completed today | 3.4 ng/mL |
| Imaging | Next surveillance ultrasound with alpha-fetoprotein | Every six months | Due | February |
| Imaging | Liver stiffness after cure | A year after cure (Baveno VII) | Due | Next summer, with hepatology |
| Referral | Liver transplant evaluation | With decompensation or MELD-Na of 15 or more | Not indicated | Compensated; MELD-Na 6 |
| Medication safety | Hepatitis A vaccination, dose 2 | Six months or more after dose 1 | Completed today | Given today; series complete |
| Laboratory | Glucose control: A1c with sensor data | Every three months when therapy changes | Completed today | A1c 6.3%; glucose management indicator 6.8%; fasting glucose 112 mg/dL |
| Referral | Diabetic eye examination | Yearly | Up to date | Done in June: no retinopathy |
| Medication safety | Zoledronic acid | Yearly | Up to date | Given eleven weeks ago; next in nine months, after a calcium check |
| Examination | Signs of decompensation (ascites, encephalopathy, jaundice, bleeding) | Each visit in cirrhosis | Completed today | None |
| Self-management | Falls and fracture risk | Each visit | Completed today | No falls |
| Survey | Alcohol use (AUDIT-C) | Each visit in liver disease | Completed today | AUDIT-C 0 |
| Survey | Pain score and function | Each visit | Completed today | 4 of 10; walking 30 minutes |
| Survey | Depression screen (PHQ-9) | At diagnosis and when treatment changes | Completed today | PHQ-9 3 |
Goal progress:
Immunizations given today: Hepatitis A vaccine, adult, dose 2 of 2 [S]
Guideline basis: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023); de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021); Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Preventive visit next month. Ultrasound with alpha-fetoprotein in February. Hepatology review with liver stiffness a year after cure. Call for abdominal swelling, black stools, vomiting of blood, confusion or yellow eyes. Next scheduled visit 2026-09-21: periodic adult preventive visit. [S]